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The human tissue kallikreins are secreted serine proteases, encoded by a group of homologous genes clustered in tandem on
chromosome 19q13.3-4. Human kallikrein 6 and human kallikrein 10 are two new members of this family. Recently, we
developed highly sensitive and speciﬁc immunoﬂuorometric assays for human kallikrein 6 and human kallikrein 10, which allow
for their quantiﬁcation in tissue extracts and biological ﬂuids. Both human kallikrein 6 and human kallikrein 10 are found to be
down-regulated in breast cancer cell lines, suggesting that they may be involved in breast cancer pathogenesis and progression.
In this study, we investigated the potential value of human kallikrein 6 and human kallikrein 10 as prognostic and predictive
factors in breast cancer. We quantiﬁed human kallikrein 6 and human kallikrein 10 protein levels in 749 breast tumour
cytosolic extracts and correlated this data with various clinicopathological variables and patient outcomes. Human kallikrein 6
and human kallikrein 10 are positively correlated with each other. Higher human kallikrein 6 and human kallikrein 10 protein
levels are associated with younger age, pre-menopausal, status and tumours which are negative for oestrogen and
progesterone receptors. No correlation was found between human kallikrein 6 and human kallikrein 10 levels and tumour size,
grade, and nodal status. Survival analysis showed that neither human kallikrein 6 nor human kallikrein 10 are related to the rate
of relapse-free and overall survival. In the analysis with respect to response to tamoxifen therapy, although human kallikrein 6
levels were not associated with tamoxifen responsiveness, higher levels of human kallikrein 10 were signiﬁcantly associated
with a poor response rate. This association remained signiﬁcant in the multivariate analysis. Furthermore, higher human
kallikrein 10 levels were signiﬁcantly related with a short progression-free and post-relapse overall survival after start of
tamoxifen treatment for advanced disease. Taken together, our results suggest that although human kallikrein 6 and human
kallikrein 10 are not prognostic markers for breast cancer, human kallikrein 10 is an independent predictive marker for
response of tamoxifen therapy.
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The human tissue kallikreins are secreted serine proteases,
encoded by a family of genes clustered in tandem on chromo-
some 19q13.3-4. All kallikreins share important similarities,
including signiﬁcant sequence homologies at both the DNA
and protein level (Yousef and Diamandis, 2001). Initially, it
was thought that in humans, this gene family consists of three
members, including human kallikrein 1 (pancreatic/renal kallik-
rein), human kallikrein 2 (glandular kallikrein), and human
kallikrein 3 (prostate speciﬁc antigen). Recently, 12 novel kallik-
rein-like genes were discovered in the same chromosomal region
and their encoded proteins are considered as new members of
the human kallikrein family. These new serine proteases were
initially given different empirical names. A new nomenclature
scheme has now been approved (Diamandis et al, 2000a) and
the genes are known as KLK1 to KLK15 and the proteins as
hK1 to hK15. This new nomenclature will be used in this study.
hK6 (also known as Zyme/Protease M/Neurosin) was indepen-
dently cloned by three groups of investigators. Using polymerase
chain reaction with degenerative primers for conserved regions in
serine protease genes, hK6 was identiﬁed from Alzheimer’s
disease brain and the colon adenocarcinoma cell line colo 201,
respectively (Little et al, 1997; Yamashiro et al, 1997). Mean-
while, by differential display, the same gene was cloned from a
breast cancer cell line (Anisowicz et al, 1996). hK6 is a serine
protease of 244 amino acids in length. Although it is highly
expressed in the brain, it is also present in many other tissues
and biological ﬂuids, as shown by RT–PCR, immunoassay and
immunohistochemistry (Yousef et al, 1999; Diamandis et al,
2000b; Petraki et al, 2001).
Human kallikrein 10 (hK10; also known as the normal epithe-
lial cell-speciﬁc 1 gene) was discovered with subtractive
hybridisation between normal and immortalised breast epithelial
cell lines (Liu et al, 1996). This serine protease is composed of
276 amino acids. hK10 was found to be present in diverse
tissues, such as breast, ovary, and prostate as well as in many
biological ﬂuids (Liu et al, 1996; Luo et al, 1998, 2001a).
The physiological functions of hK6 and hK10 are still not
clear. Among all human tissue kallikreins, only hK1 has true
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www.bjcancer.comkallikrein function, which, is deﬁned as the ability to release
kinins from kininogen (Clements, 1997; Yousef and Diamandis,
2001). All other kallikreins, presumably, act upon other
substrates to mediate their physiological function. hK6 is
predicted to have trypsin-like serine protease activity, whereas,
hK10 is chymotrypsin-like. Several lines of evidence suggest that
hK6 and hK10 actively participate in various pathological
processes. Little et al (1997) showed that hK6 has amyloidogenic
potential in the brain and may play a role in Alzheimer’s disease.
Others have demonstrated that hK6 is down regulated in aggres-
sive forms of breast cancer, implicating that hK6 may be
involved in breast cancer progression (Anisowicz et al, 1996).
hK10 was also found to be down regulated in various cancer cell
lines, including those from breast and prostate (Liu et al, 1996,
Goyal et al, 1998). In testicular cancer, hK10 expression is signif-
icantly reduced or undetected in the tumour tissue compared to
its adjacent normal tissue (Luo et al, 2001b). Furthermore, over-
expression of hK10 can suppress tumour formation in nude
mice, suggesting that it may function as a tumour suppressor
(Goyal et al, 1998).
The best known marker for prostate cancer, PSA or hK3, is
a member of the kallikrein family (Stamey et al, 1987; Oester-
ling, 1991). Since hK6 and hK10 seem to be involved in various
diseases, and especially cancer, we speculated that their protein
levels may change during disease initiation and progression
and therefore, they may also be potential disease biomarkers.
Recently, we developed highly sensitive and speciﬁc immuno-
ﬂuorometric assays for hK6 and hK10 (Diamandis et al,
2000b; Luo et al, 2001a) and provided evidence that these
proteins are potential serum biomarkers for ovarian cancer
(Diamandis et al, 2000c; Luo et al, 2001c) as well as prognostic
markers for the disease (Luo et al, 2001d; Hoffman et al, 2002,
submitted). We have also previously shown that both hK6 and
hK10 are measurable in breast cancer cytosolic extracts
(Diamandis et al, 2000b; Luo et al, 2001a). We have thus
hypothesised that hK6 and hK10 may have a role as prognostic
or predictive markers for breast cancer. In order to examine
this hypothesis, we measured quantitatively levels of hK6 and
hK10 in breast tumour cytosolic extracts and examined their
relationship with clinicopathological variables including survival
and response to tamoxifen treatment.
MATERIALS AND METHODS
Patients and tissue samples
Human kallikrein 6 and human kallikrein 10 levels were deter-
mined in cytosol preparations (as described below) from 749
primary invasive breast tumours collected between 1978 and
1990. Selection of samples was based on the availability of stored
cytosol extracts (in liquid nitrogen), which remained after
routine ER and PgR analyses and PSA as described earlier
(Foekens et al, 1999). Of the 749 patients, 718 were eligible
for analysis of relapse-free survival and overall survival according
to the criteria described before (Foekens et al, 2000). Inoperable
T4 tumours were not included. Patient tissues that were sampled
after neoadjuvant treatment, or obtained from a biopsy speci-
men, were excluded. Patients who were referred to our
institute more than 100 days after primary surgery and patients
with distant metastasis at the time of primary surgery (M1
patients; staging according to the International Union Against
Cancer TNM (tumour-node-metastasis) classiﬁcation (Sherman
and Hossfeld, 1990) were excluded from the analyses of
relapse-free and overall survival. The latter patients were not
necessarily excluded from the analysis of the response to ﬁrst-line
treatment with tamoxifen for advanced disease. In fact, these 31
patients were added to those who were eligible for our analysis
of the response to tamoxifen therapy.
Analysis of relapse-free and overall survival was performed on
718 patients with primary operable breast cancer. Median age of
these patients at the time of surgery was 55 years (range 24–89
years). Three hundred and six patients were pre-menopausal and
412 were post-menopausal at the time of primary surgery. Three
hundred and ninety-ﬁve patients had undergone modiﬁed
mastectomy and 323 patients, breast conserving treatment.
Radiotherapy was given to 623 patients (87%): on the breast/
thoracic wall in 503 patients and/or on the axilla in 272 patients,
and/or parasternal and/or supraclavicular lymph nodes in 330
patients. T1 tumours (42 cm) were present in 255 patients
(36%), T2 tumours (42–5 cm) in 360 patients (50%), T3
tumours (45 cm) in 58 patients (8%), and operable T4 tumours
in 45 patients (6%). Pathological examination was as described
previously (Foekens et al, 1989) and the histological differentia-
tion grade was coded as poor in 425 patients (59%), moderate
in 118 patients (16%), well in 10 patients (1%), and unknown
for 165 patients (23%). None of the 297 node-negative patients
received systemic adjuvant therapy. Of the 421 node-positive
patients, 196 had one to three nodes involved (27%), and 225
more than three nodes involved (31%). Of these patients, adju-
vant chemotherapy (mainly cyclophosphamide/methotrexate/5-
ﬂuorouracil, CMF) was given to 138 patients (mainly pre-meno-
pausal patients), whereas 62 patients received adjuvant hormonal
therapy (mainly post-menopausal patients), either alone (51
patients) or in combination with chemotherapy (11 patients).
All patients were examined routinely every 3–6 months during
the ﬁrst 5 years of follow-up and once a year thereafter. Of
the 718 patients included, 420 (59%) showed evidence of disease
during follow-up and count as failures in the analysis of relapse-
free survival. Forty-eight patients (7%) died without evidence of
disease and were censored at last follow-up in the analysis of
relapse-free survival. Three hundred and eighteen patients
(44%) died after a previous relapse. A total of 366 (48+318)
patients (51%) were failures in the analysis of overall survival.
The median follow-up period of patients alive (n=352) was
118 months (range, 16–211 months).
The following inclusion criteria were used for patients who
received tamoxifen: patients with advanced disease who were
treated with ﬁrst-line tamoxifen therapy (40 mg day
71) and were
not exposed to hormonal treatment at an earlier stage (hormono
naive). Of the 420 patients of the 718 patients who relapsed, 211
subsequently received tamoxifen as ﬁrst-line treatment. The
remaining patients were treated by chemotherapy surgery, radio-
therapy, other forms of systemic treatment, or died without
further treatment. Following the same inclusion criteria, the
subset of 211 patients was expanded with 31 patients who were
previously excluded for analysis of relapse-free and overall survi-
val. The median age of the total of 242 patients at start of
treatment for advanced disease with tamoxifen was 61 years
(range 33–87 years). Twenty-three per cent (n=56) of the
patients were pre-menopausal, and 77% (n=186) post-menopau-
sal. The ﬁrst dominant site of disease was visceral in 89 patients,
bone in 114 patients, and soft tissue in 39 patients. Seventeen
patients (7%) had metastatic disease (M1 patients) at time of
primary surgery. One-hundred and sixty-six patients (69%) had
a disease-free interval (DFI) of 412 months between primary
tumour removal and ﬁrst recurrence. Only 51 patients had been
treated with adjuvant polychemotherapy (CMF in 42 patients;
FAC or FEC in nine patients). The median follow-up of patients
still alive after start of tamoxifen treatment was 34 months
(range 2–111 months). Thirty-one patients were still alive at
the end of the present study, whereas 211 patients (87%) had
died. On tamoxifen therapy, tumour progression occurred in
229 patients (95%) during follow-up. Of these patients, 151 were
subsequently treated with one or more additional hormonal
agents (mostly high-dose progestins), and to date, 126 patients
have received systemic chemotherapy after the development of
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(11), 1790–1796hormonal resistance (mainly CMF or FAC). The length of
progression-free survival was deﬁned as the time from the start
of treatment for advanced disease until the start of next treat-
ment because of progressive disease or until the time of
intercurrent death. All patients were assessed by standard Inter-
national Union Against Cancer criteria for objective response
(complete remission, CR; partial remission, PR). Patients with
no change for 46 months (stable disease, SDis) have a post-
relapse overall survival similar to patients with partial remission
(Ravdin et al, 1992; Foekens et al, 1994a). Therefore, for overall
response, objective response and stable disease were combined
(CR+PR+SDis).
Assay of ER and PgR
Tumour tissues were stored in liquid nitrogen and pulverised in
the frozen state with a microdismembrator as recommended by
the European Organization for Research and Treatment of
Cancer (EORTC) for processing of breast tumour tissue for
cytosolic ER and PgR determinations (EORTC Breast Cancer
Cooperative Group, 1980). The resulting tissue powder was
suspended in EORTC receptor buffer (10 mM dipotassium
chloride EDTA, 3 mM sodium azide, 10 mM monothioglycerol,
and 10% v v
71 glycerol, pH 7.4). The suspension was centri-
fuged for 30 min at 1000006g to obtain the supernatant
fraction (cytosol). ER and PgR levels were determined by ligand
binding assay or with enzyme immunoassay as described
previously (Foekens et al, 1989). The cut-off point used to clas-
sify tumours as ER or PgR positive and negative was
10 fmol mg
71 protein.
Quantiﬁcation of hK6 and hK10 by immunoﬂuorometric
assays
The concentrations of hK6 and hK10 in the breast tumour cyto-
solic extracts were determined by immunoassays, as previously
described (Diamandis et al, 2000b; Luo et al, 2001a). The hK6
assay is a sandwich-type immunoassay utilising mouse and rabbit
anti-hK6 polyclonal sera. Brieﬂy, mouse anti-hK6 polyclonal anti-
serum was ﬁrst captured by sheep anti-mouse IgG-coated
microtiter plates. Standards or samples were then added. Subse-
quently, rabbit anti-hK6 polyclonal antiserum and alkaline
phosphatase conjugated-goat anti-rabbit IgG were sequentially
applied to the plates. Finally, an alkaline phosphatase substrate
was added and the signal was measured by time-resolved
ﬂuorescence. hK10 immunoassay is also a sandwich-type
immunoassay, incorporating one monoclonal capture antibody
and rabbit anti-hK10 polyclonal antiserum. In this assay, the
hK10 monoclonal antibody was ﬁrst directly coated on the poly-
styrene plates. Standards and samples were pipetted into each
well, incubated and washed. Biotinylated rabbit anti-hK10 poly-
clonal antiserum was then added, incubated and washed.
Finally, alkaline phosphatase conjugated-streptavidin was applied
and the signal was detected as above, with time-resolved ﬂuores-
cence. All tumour extracts were measured in duplicate. hK6 and
hK10 concentrations in mgl
71 were converted to mg of hK6 or
hK10 mg
71 of total protein to adjust for the amount of tumour
tissue extracted.
Statistics
The strength of the associations of hK6 and hK10 with continuous
variables was tested with Spearman rank correlation (rs). The
strength of the association of hK6 and hK10 (used as continuous
variables) with other variables (used as grouping variable) was
tested with the non-parametric Wilcoxon Rank-Sum test or Krus-
kal-Wallis test, followed by a Wilcoxon-type test for trend across
ordered groups where appropriate. Survival probabilities were
calculated by the actuarial method of Kaplan and Meier (1958).
The logrank test was used to test for differences between survival
curves. Both univariate and multivariate analyses were performed
using the Cox proportional hazards model. The likelihood ratio
test in the Cox regression models was used to test for differences
and for interactions. The relationship of predictive factors with
response to therapy was examined with logistic regression analysis.
In our search for the best categorisation of hK6 and hK10, we have
used isotonic regression analysis (Barlow et al, 1972; Foekens et al,
1994b) using the overall response rate as endpoint in those patients
who received tamoxifen therapy for advanced disease. All compu-
tations were done with the STATA statistical package, release 6.0
(STATA Corp., College Station, TX, USA). All P values are two-
sided.
RESULTS
hK6 and hK10 levels and patient and tumour
characteristics
The levels of hK6 and hK10 in primary breast tumour cytosols
ranged from 0–250 mgm g
71 of protein (median, 1.0 mgm g
71
of protein) and from 0–16.3 mgm g
71 protein (median,
39 ng mg
71 of protein), respectively. Table 1 shows that younger
and pre-menopausal patients more often had higher levels (above
the median value) of hK6 and hK10, compared with older and
post-menopausal patients. The Spearman rank correlations (rs)
between the levels of hK6 and hK10 with age were 70.20 and
70.12, respectively. hK6 and hK10 levels were not signiﬁcantly
related with size or grade of the primary tumour. Tumours of
node-negative patients more often had a higher level of hK6,
while such an association was not present for hK10. The levels
of hK6 and hK10 were negatively correlated with those of ER
and PgR, with the steroid hormone-receptor negative tumours
showing more often higher values (Table 1). The rs was 70.35
for hK6 and ER, and 70.14 for hK6 and PgR. Those between
hK10 and ER and PgR were 70.20 of 70.10, respectively.
The levels of hK6 and hK10 were positively correlated with each
other (rs=0.35, P50.001).
Relationship of hK6 and hK10 with relapse-free and overall
survival
Of the 749 patients included in the study, 718 were eligible for
analysis of relapse-free and overall survival. When studying hK6
or hK10 as log-transformed continuous variables, or as dichot-
omised variables at their median levels, in the analysis of
relapse-free and overall survival, neither of them was signiﬁ-
cantly related with the rate of relapse in these 718 patients.
In contrast, both in the analysis of relapse-free and overall
survival, the traditional prognostic factors younger age (P=0.04
and P50.001), larger tumour size (for both, P50.001), the
number of positive lymph nodes (for both, P50.001), and poor
tumour grade (for both, P=0.01), were all signiﬁcantly asso-
ciated with a worse prognosis. ER-positive or PgR-positive
tumours were associated with a favourable prognosis, although
the association of ER with relapse-free survival was not of
statistical signiﬁcance (P=0.56 and P=0.02 in the analysis of
relapse-free survival, and P=0.05 and P50.001 in the analysis
of overall survival, respectively).
Tamoxifen therapy: univariate analyses as a function of
hK16 and hK10 status
Of the 242 patients who received tamoxifen as ﬁrst-line treat-
ment for advanced disease, 127 (52%) responded (eight CR, 27
PR, 92 SDis). The median duration of response in these respon-
ders was 14 months. Using logistic regression analysis, it was
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with a higher rate of response on tamoxifen treatment compared
with younger age and pre-menopausal status (Table 2). In
patients with a DFI512 months (34% response, OR set at 1)
the fraction of responding patients was smaller than in patients
with a DFI 1 year (61% response; OR, 2.99). Patients who
relapsed to the viscera showed worse rate of response (OR,
0.44) compared with those who relapsed to the bone (OR,
0.69) or to soft tissues (OR, 1). Patients with ER-positive
tumours had a more favourable response rate (55% response;
OR, 2.17) than patients with ER-negative (36% response; OR,
1). When ER was analysed as a log-transformed continuous vari-
able, higher levels were signiﬁcantly associated with a higher
response rate as well (P=0.003). In these patients, PgR and
hK6 were not signiﬁcantly associated with the rate of response
when analysed as dichotomised variables (at 10 fmol mg
71 of
protein and at the median level of 1.0 mgm g
71 of protein,
respectively). When analysed as log-transformed continuous vari-
able, higher levels of PgR were associated with a favourable
response (P=0.008), but hK6 was not (P=0.24). hK6 was there-
fore not further considered in the present study. Adjuvant
chemotherapy was not related to the rate of response to tamox-
ifen treatment. When analysing the relationship of continuous
tumour hK10 levels with response, it appeared that increasing
levels of hK10 were associated with a lower response rate
(P=0.01). Using isotonic regression analysis, 86 ng hK10 mg
71
of protein was chosen as cut point to classify advanced breast
cancer patients as hK10-positive and hK10-negative. Compared
with the 192 hK10-negative patients (57% response (15%
CR+PR, 42% SDis); OR, 1), the 50 hK10-positive patients
showed a worse rate of response (36% response (12% CR+PR,
24% SDis), OR=0.43; P=0.01). Furthermore, the duration of
response in the 192 hK10-negative patients was 9.0 months
compared with 4.2 months for the 50 hK10-positive patients.
Similarly the median overall survival time after start of tamoxifen
treatment was longer for hK10-negative patients compared with
hK10-positive patients (25 and 17 months, respectively). In
Cox univariate regression analysis using continuous hK10 levels,
higher levels signiﬁcantly predicted a poor progression-free survi-
val (P=0.04) and post-relapse overall survival (P=0.01). Similarly,
when using hK10 as a dichotomised variable, hK10 positivity was
associated with a rapid disease progression (Figure 1A, P=0.003)
and an early death (Figure 1B, P=0.004) after start of tamoxifen
treatment.
Tamoxifen therapy: multivariate analysis as a function of
hK10 status
The independent relationship of hK10 status levels with the rate
of response to tamoxifen treatment in advanced breast cancer
was studied using multivariate logistic regression analysis. hK10
positivity was associated with a poor rate of response (OR,
0.47; 95% CI, 0.23-0.94; P=0.03). In addition to hK10, combined
young age and post-menopausal status (P50.01), a short DFI
(P50.001), and visceral metastasis (P=0.02) were independent
factors which signiﬁcantly predicted a poor response rate in
the multivariate analysis. ER or PgR included either as a dichot-
omised variable or as log-transformed continuous variable, did
not signiﬁcantly contribute to the multivariate model. When
hK10 was added as a log-transformed continuous variable instead
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Table 1 Relationships of hK6 and hK10 with patient and tumour characteristics
hK6-high
a hK10-high
a
Characteristic Frequency
b Number (%) P Number (%) P
All patients 749 373 (50) 376 (50)
Age (years) 50.001
c 0.001
c
440 93 58 (62) 52 (56)
41–55 280 158 (56) 147 (53)
56–70 247 108 (44) 123 (50)
470 129 49 (38) 54 (42)
Menopausal status 50.001
d 50.001
d
Pre-menopausal 312 186 (60) 177 (57)
Post-menopausal 437 187 (43) 199 (46)
T-status 0.26
e 0.21
e
T1 258 123 (48) 129 (50)
T2 375 192 (51) 197 (53)
T3/4 116 58 (50) 50 (43)
N-status 0.02
e 0.81
e
N0 300 166 (55) 152 (51)
N1–3 201 89 (44) 101 (50)
N43 241 114 (47) 118 (49)
Histologic grade 0.96
e 0.38
e
Poor 443 216 (49) 214 (48)
Moderate 125 64 (51) 72 (58)
Good 10 5 (50) 4 (40)
ER-status
f 50.001
c 50.001
c
Negative 180 121 (67) 116 (64)
Positive 567 252 (44) 259 (46)
PgR-status
f 50.001
c 0.009
c
Negative 220 122 (55) 122 (55)
Positive 506 242 (48) 241 (48)
aAbove median value of 1.0 mgm g
71 of protein for hK6 and 539.0 ng mg
71 of protein for hK10.
bDue to missing values numbers do not always add up to 749.
cP for Spearman rank correlation.
dP
for Wilcoxon Rank-Sum test.
eP for Kruskal-Wallis test.
fCut points used for ER and PgR:
10 fmol mg
71 of protein.
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contribution of hK10 was of borderline statistical signiﬁcance
(P=0.06). There were no statistically signiﬁcant interactions
between hK10 status with any of the other variables included
in the multivariate model for the rate of response to tamoxifen
treatment.
DISCUSSION
In this study, we measured hK6 and hK10 protein levels in
breast tumour cytosols and found that they were positively
correlated with each other, but negatively associated with ER
and PgR. High hK10 is an independent predictor of response
to tamoxifen therapy. hK6 and hK10, as well as other kallikreins,
coexist in many tissues and biological ﬂuids (Yousef and
Diamandis, 2001; Diamandis et al, 2000b; Luo et al, 2001a). It
has been reported that hK2 is able to activate hK3 by cleaving
pro-hK3 (Kumar et al, 1997; Takayama et al, 1997). This obser-
vation suggests that kallikrein enzymes may participate in
catalytic cascades and functionally interact with each other; for
instance, one activates/inactivates another (Yousef and Diaman-
dis, 2001). The positive correlation between hK6 and hK10 in
breast tumour cytosols supports this hypothesis.
Due to the lack of knowledge on the physiological function
of hK10 in breast tissue, the rationale underlying the reverse
correlation between hK10 and ER and PgR is not clear. It is
well documented that ER-negative tumours grow more aggres-
sively and tend to metastasise more than ER-positive tumours
(Andry et al, 1989; Winstanley et al, 1991). It is possible that
hK10, a serine protease, may be associated with aggressiveness
and metastatic potential of tumour cells. In another study, we
showed that in ovarian cancer, high hK10 protein levels in
tumour extracts correlate with late disease stage and poor survi-
val (Luo et al, 2001d). These data support an association
between hK10 overexpression and breast or ovarian cancer
aggressiveness. The following two hypotheses may explain this
association:
First, hK10 may participate in a pathway that involves promo-
tion of cancer cell-growth. Previously, using a cell culture system,
we found that hK10 mRNA level is up-regulated upon oestradiol
and norgestrel stimulation in the breast cancer cell line BT-474
(Luo et al, 2000). Our further investigations demonstrated that
hK10 was increased at both the mRNA and protein level not
only by oestradiol and norgestrel, but also by other steroid
hormones including dihydrotestosterone, dexamethasone and
aldosterone in various breast cancer cell lines, such as MCF-7
and T-47D (unpublished data). Other investigators have reported
steroid hormone receptor activation by non-steroidal ligands,
including growth factors (Klocker et al, 1999). It is thus possible
that hK10 may be up regulated by a variety of mechanisms in
cancer. The enzymatic activity of hK10 may then be crucial for
activation of downstream growth factors or receptors, as it has
been shown for other serine proteases, including hK3, another
member of the kallikrein family (Killian et al, 1993; Coughlin,
2000; Diamandis, 2000d). This activity may promote increased
cell growth.
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Table 2 Univariate analysis for response to ﬁrst-line tamoxifen therapy in
patients with advanced breast cancer
Response
Frequency rate (%) P OR
a (95% CI)
b
All patients 242 52
Menopausal status
c
Pre-menopausal 56 38 1
Post-menopausal 186 57 0.01 2.21 (1.20–4.08)
Age (years)
c
440 12 33 1
41–55 82 44 1.57 (0.44–5.61)
56–70 79 56 2.51 (0.70–9.04)
470 69 62 0.06 3.31 (0.91–12.1)
First site of relapse
Soft tissue 39 64 1
Bone 114 55 0.69 (0.33–1.47)
Viscera 89 44 0.08 0.44 (0.20–0.95)
Disease-free interval
51 year 76 34 1
51 year 166 61 50.001 2.99 (1.69–5.27)
ER status
d
Negative 36 36 1
Positive 205 55 0.04 2.17 (1.04–4.53)
PgR status
d
Negative 62 47 1
Positive 171 55 0.27 1.39 (0.78–2.49)
hK6 levels
e
Low 129 54 1
High 113 50 0.55 0.86 (0.52–1.42)
hK10 status
f
Negative 192 57 1
Positive 50 36 0.01 0.43 (0.22–0.82)
aOdds ratio.
b95% conﬁdence interval.
cAt time of start of ﬁrst-line tamoxifen treatment.
dCut
points: 10 fmol mg
71 of protein. One missing value for ER and 9 for PgR.
eLow:
41.0 mgm g
71 of protein, and high: 41.0 mgm g
71 of protein.
fNegative: 486 ng mg
71
of protein, and positive: 486 ng mg
71 of protein.
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promotion of cancer cell metastasis. To metastasise, tumour cells
turn on expression of factors that facilitate destruction of extra-
cellular barriers (Liotta et al, 1991). Proteases are widely believed
to be involved in these processes (Aznavoorian et al, 1993; Duffy,
1992). Therefore, the amount of proteases released by the
primary tumour may reﬂect the ability of the tumour to spread.
Overexpression of proteases has been reported in many cancers,
such as of urokinase plasminogen activator (Look and Foekens,
1999), cathepsin D (Thorpe et al, 1989), and matrix metallopro-
teinase (Daidone et al, 1991). We speculate that hK10 may
participate in a cascade reaction, which catalyses the breakdown
of extracellular matrix, and thus, overexpression of hK10 may
facilitate tumour migration.
It is well established that ER status correlates well with
response to tamoxifen treatment. Still, a sizeable fraction of
ER-negative patients do respond to tamoxifen, while not all of
ER-positive patients respond. In this study, we found that
hK10 levels can independently predict which patients will or will
not respond to tamoxifen. These data are further reﬂected in
both progression-free survival and post-relapse overall survival
analysis (Figure 1). Interestingly, hK10 is the second member
of this family whose increased expression correlates with poor
response to tamoxifen therapy in breast cancer. We previously
(Foekens et al, 1999) studied the other member, hK3 (PSA).
In summary, our study represents the ﬁrst investigation show-
ing that high hK10 protein levels are associated with low ER and
PgR levels in breast tumours and that high hK10 levels in
tumour tissue are independent predictors of poor response to
tamoxifen therapy. The data presented herein should be consid-
ered as hypothesis generating and validation by an independent
set of tumours is necessary. Our data may be useful for two
purposes: (a) to shed more light on the biological mechanisms
of tamoxifen resistance and the role of kallikreins in this process
and (b) to identify additional biomarkers which have indepen-
dent potential as predictors of therapeutic response in cancer.
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with tamoxifen. Patients at risk are indicated. Cut point used for hK10,
86 ng mg
71 protein. RHR, relative hazards ratio. CI, conﬁdence interval.
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